Introduction
Current treatment for hemophila-related bleeding episodes utilizes intravenous infusion of purified and recombinant factor protein, which is effective, yet transient because of the short half-life of the proteins. This treatment is expensive, restricts the prophylactic use of factors and can lead to crippling joint disease and susceptibility to infectious agents. Effective hemophilia gene transfer requires that a sustained, long-term (years) production of coagulation factor at therapeutic levels be generated. Thus, the method of gene delivery must be safe, and the risk of immune response to potential neoantigens must be minimal. Given recent scientific/ technical developments, genetic correction of hemophilic patients is now viewed as an achievable goal.
The factor VIII and IX gene and protein products have been extensively studied. 1, 2 Many tissues and cell types (skeletal muscle, liver, spleen and skin) are capable of producing and expressing fully modified and functional factor IX protein. A therapeutic factor level is considered to be Z2% of normal levels. This is sufficient to convert a severely affected patient with frequent spontaneous bleeding episodes (patients with o1% factor level) to a moderate or mildly affected level. Coagulation assays are standardized and animal models (knockout mice and hemophilic canines) that mimic the human phenotype are available for testing. A variety of gene transfer approaches are currently being tested both in the laboratory and in the clinic. Results of two clinical trials, using nonviral and viral-based gene transfer approaches, suggest that despite low factor levels, patients required less factor infusion and reported fewer bleeding episodes. Although neither trial included a placebo arm, these results enforce clinical observations that low levels of factor dramatically reduce spontaneous bleeding. Despite the current excitement, results point to the need for improved vectors. Here, we will review the recent advances over the past 2 years in this field that mirrors the advances in the field of gene transfer in general.
New adeno-associated virus (AAV) serotypes and lentiviral vectors have recently been studied for the production of factor VIII or IX In general, viral vectors exhibit long-term gene expression (years), whereas nonviral methods produce transi-
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New AAV serotypes and lentiviral vectors have recently been studied for the production of factor VIII or IX. Organs other than the liver can be used as 'factories' for factor VIII and IX production. The immune response to endogenous factor synthesis and viral vectors is a potential problem in hemophilia gene transfer. Hemophilia clinical trials using either retrovirus, AAV or ex vivo transfected fibroblasts have been carried out or are ongoing.
Prospects
Development of improved lentiviral, gutless adenovirus and alternate AAV serotype vectors is in progress Gene repair, RNA repair (Trans-splicing) offer opportunities for the treatment of hemophila. Gene-modified circulating endothelial progenitor may prove useful in the future. Gene-modified stem cell therapy may become available.
ent (weeks to months) factor expression. Hemostatic levels of factors VIII and IX were reached with first-and second-generation adenovirus vectors. Unfortunately, the exuberant cell-mediated immune response engendered by this vector leads to inflammatory response directed at transduced cells with the attendant loss of protein expression. Newer gutless adenovirus with a minimum of endogenous adenoviral genes may limit the immune response, but as a consequence gene expression is drastically reduced. AAV has recently come to the fore based on its now relative ease in preparation, ability to infect both dividing and nondividing cells, 3 and although it engenders a humoral immune response, it does not stimulate a cytotoxic lymphocyte response. Using this vector, therapeutic levels of factors IX and VIII were demonstrated in knockout mouse and hemophilic canines. Eight serotypes of AAV, have been isolated and cloned (AAV1-8). Of these AAV, type 2 was the first cloned and most extensively studied. Surprisingly, other serotypes yield factor IX at levels two logs greater than AAV-2 following skeletal muscle injection into mice 4 and produce sustained supratherapeutic factor levels leading to complete loss of the bleeding diathesis. 5 Such levels are achieved as a result of more efficient effective skeletal muscle gene transfer. Here, a linear relation exists between input vector and factor expression. A unique side benefit is lack of an immune inhibitor response presumably because of continuous production of factor as the major determinant for inducing tolerance. This result is reminiscent of immune tolerance strategies currently used in the clinic, performed by repeated infusion of factor.
In particular, AAV1 produces robust transgene expression in muscle, but the exact mechanism is unclear. Data using AAV1/EGFP suggested that the number of transduced muscle fibers infected increases significantly with AAV1 compared to AAV2 (see Figure 1) . A linear relation between circulating levels of canine factor IX protein and AAV1 dose suggests that this result is most likely because of the number of myocytes productively infected. One working hypothesis explaining the serotype transduction differences lies in the level of virus specificity for binding cell receptors. At present, the receptor for AAV type 1 has not been identified but appears distinct from type 2, that is, not inhibited by heparin.
AAV serotypes 7 and 8 recently isolated from primates infected with high-dose adenovirus 6 are not neutralized by heterologous antisera raised to the other serotypes. Recombinant serotypes 7 and 8 vector particles carrying the alpha-1-antitrypsin cDNA were compared for transducing effectiveness in mice. AAV7 was equivalent to AAV1 in efficient expression in skeletal muscle, whereas AAV8 expressed at a 10 to 100-fold greater rate in liverdirected expression than all other serotypes. These data confirm that relatively small differences in the capsid structure produce striking differences in transgene expression in a wide variety of tissues.
Lentiviral vectors have the potential to play an important role in hemophilia gene therapy. One study used human immunodeficiency virus (HIV)-based lentiviral vectors containing human factors VIII or IX cDNA expression for portal vein injection into C57Bl/6 mice. Increasing doses of hFIX-expressing lentivirus resulted in a dose-dependent, sustained increase in serum hFIX levels up to approximately 50-60 ng/ml. Partial hepatectomy resulted in a 4-to 6-fold increase in serum hFIX of up to 350 ng/ml compared with the nonhepatectomized animals. The expression of plasma hFVIII reached 30 ng/ml (15% of normal), but was transient as the plasma levels fell concomitant with the formation of antihFVIII antibodies. 7 Owing to the potential safety issues using an HIVbased vector, an alternate approach is to utilize plasmidbased approaches that carry genetic elements that promote integration. Early attempts using such a system have provided encouraging results. 8 Organs other than the liver can be used as sources for factor VIII and IX production
The liver is the principal organ synthesizing the coagulation factors. However, other organs can synthesize factors VIII and factor IX. Factor IX can be expressed from skeletal muscle, fibroblasts, kerintinocytes, intestinal mucosa, cells lining the amniotic cavity and marrow stroma. 9 Factor VIII transgene expressing circulating endothelial cells are capable of secreting high levels of factor VIII for a sustained period in animal models. 10 Circulating endothelial cells obtained from peripheral blood are expanded ex vivo and then genetically modified to express a gene of interest. The biochemical elements necessary for high-level factor expression including the endogenous coexpression of factor VIII and vWF may explain the high factor levels observed in vivo. The regulation of infused endothelial precursor cell growth kinetics and half-life of fully differentiated endothelium remains to be determined. Ex vivo gene transfer of hematopoietic progenitor cells and marrow stroma are also capable of factor VIII secretion in vivo.
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The immune response to endogenous factor synthesis and viral vectors is a potential problem in hemophilia gene transfer
The antibody responses to exogenous factor replacement, termed inhibitors, effect nearly 20% of factor VIII patients and 3% of factor IX patients. Inhibitory antibodies that Gene therapy for the hemophilias CE Walsh bind to the particular regions of the factor molecule inactivate by changing factor protein conformation. 2 In general, the immune response may in part be related to the type of mutation. For example, a large deletion in the factor VIII gene and complete loss of protein typically leads to a greater incidence of inhibitor formation. Bleeding episodes of patients with inhibitors are difficult to manage, relying on activated bypass factors and recombinant factor VIIa. 12 Will a constant source of factor engender high titer inhibitory antibodies negating any positive benefit and with consequences of worsening bleeding? The clinical trials described below carefully screen for noninhibitor patients or patients with frequent infusions where the chances of inhibitor are reduced. CD4+ subset activation in humans and Th-1 and Th-2 lymphocytes in mice suggests that both MHC class I and II mechanisms are involved. Involvement of both central (marrow, thymus) and peripheral (lymph nodes, Peyers patch) tolerance mechanisms to factor VIII is described but poorly understood. [13] [14] [15] In addition to the immune response to the transgene factor proteins, immune response to viral vectors is well described for adenovirus and AAV and thus prevent readministration of vector.
Hemophilia clinical trials using either retrovirus, AAV or ex vivo transfected fibroblasts have been carried out or are ongoing
Within the past 2 years, five gene transfer trials were approved (three for hemophilia A, two for hemophilia B) in the US. Biotech firms that developed vectors specifically for factors VIII and IX sponsor all five trials. In a phase I dose escalation study, 13 subjects with hemophilia A received by peripheral intravenous infusion an amphotropic retroviral vector carrying a B-domain deleted human factor VIII gene. Infusions were administered to patients with HIV and HCV infections and were well-tolerated. Factor VIII was measured and no subject had sustained repeated FVIII levels 41% of normal levels. Patients were treated with vector ranging from 3 Â 10 7 to 9 Â 10 8 vp/kg. Overall, there was no significant change in bleeding frequency. And there was no correlation between vector dose and time to FVIII activity response. This clinical outcome is consistent with the limited capability of retroviral integration into nondividing liver cells and the lack of a liver-specific promoter in the retroviral vector used.
A trial using an AAV2 vector carrying the human factor IX cDNA injected intramuscularly was carried out in eight patients in a dose escalation study. 16, 17 One patient receiving the lowest dose (2 Â 10 11 vp/kg) was reported to maintain factor levels at 1-2% and reported a 50% reduction in factor usage and bleeding episodes for a period up to 40 months postinjection. No evidence of inhibitor was reported despite preclinical data in dogs of a transient inhibitory response. Virus dissemination was transiently detectable in all body fluids, excluding semen. At higher doses, no significant plasma factor levels were reported. However, reduced frequency of factor usage was one end point signifying treatment effectiveness. Molecular analysis of virus dissemination was detectable in all body fluids (saliva, blood and urine) but not in germ cells. All patients had low (1:100-1000) preinjection anti-AAV2 neutralizing titers that increased after vector administration. An increase in the number of injection sites from 10 to 90 produced no significant increase in factor level. High titer neutralizing antibodies to AAV developed in all patients at levels sufficient to preclude readministration of vector. Muscle biopsy confirmed previous observations in animals that slow twitch muscle fibers expressed factor IX.
A dose-escalation study based on AAV2 vectors carrying human factor IX cassettes delivered via the hepatic artery has begun. Two patients received the lowest dose of virus (2 Â 10 11 /kg) via intra-arterial delivery without adverse effects. However, the trial was temporarily halted because of detection of the transgene in seminal fluid. Trial resumption was based on data that germ cells were not infected with the virus. No detectable levels of factor FIX were observed above background in the two patients receiving the lowest dose of vector. Two patients received moderate doses of vector (1 Â 10 12 /kg). One patient developed FIX levels up to 10-12% within 2-3 weeks after injection; however, factor levels subsequently dropped coincident with an elevation of the liver transaminases. No data were presented on the second patient. Whether this represents toxicity of the vector at this dose remains to be determined. It is interesting to note that based on dose-response experiments in hemophilic dogs, this moderate dose of virus produced 4-14% of canine FIX for 1-2 years without significant toxicity.
A nonviral approach used a factor VIII plasmid electroporated into autologous skin fibroblasts: cells were expanded in vitro and 100 or 400 million cells injected into the greater omentum. 18 Levels of factor VIII above pretreatment levels were measured in four of six patients with either a concommitant reduction in the use of recombinant factor VIII or decreased number of spontaneous bleeding episodes. However, factor VIII decreased to pretreatment levels in all the patients after 12 months. The explanation for the decline in factor expression may have been because of gene silencing, immunological clearance or senescence of the fibroblasts after reimplantation.
What do these clinical results tell us? No significant toxicity in any of the patients was reported. Furthermore, the factor levels predicted from animal models were not observed in patients. Thus, although testing of new factor proteins in hemophilic animals is traditionally used because of similar pharmacokinetic profiles seen in man, such extrapolation using gene transfer vectors may not be clear-cut. A review of the preclinical data also suggests that animal studies may not be predictive of the clinical outcome. For example, vector dosing based on a vector particle-to-weight ratio produced discrepant results when comparing equivalent AAV vector dosing in mice and hemophilic dogs. Whereas experiments in hemophilic mice are dose-dependent and can produce supraphysiologic levels of factor IX (300% of normal), equivalent doses in hemophilic dogs produce factor IX at levels around 5% of normal and do not appear to be dose-dependent. 19 Recent data testing AAV2/human factor IX vectors in non-human primates produced 4-10% factor IX, 20 similar to data generated in hemophilic dogs, 21 for a period of 1 year. These outcomes reflect species differences in terms of the rate Gene therapy for the hemophilias CE Walsh of cell infectivity, gene expression, protein modification and processing. However, testing in different animal models serves to confirm the validity of each new approach.
Future prospects
RNA repair (Trans-splicing) offers opportunities for the treatment of hemophila A novel approach for genetic correction involves the use of premessenger RNA (pre-m-RNA) repair. RNA transsplicing utilizes endogenous splicing mechanisms to correct a portion of the defective RNA. A pre-mRNA is designed to base pair with a pre-mRNA transcribed from the defective gene. The pre-mRNA also contains all the requisite splicing signals that allows two independent mRNAs to splice together, resulting in a correct copy of mRNA that is translated into a normal protein. 22 The advantage of this system is that large genes, unable to be packaged into viral vectors, or genes that contain large regulatory elements could be corrected by using the smaller spliced sequences. We developed such a system for factor VIII correction . Using the factor VIII exon 16 knockout mice as a model to test trans-splicing, we demonstrated that by injecting plasmid or AAV carrying pre-mRNA encoding for exons 16-26 around 2-6% of factor VIII, that prevented bleeding challenge, was generated for 3-5 days and 3-4 months, respectively (Chao et al, submitted). As trans-splicing efficiency improves, this may be useful for the treatment of autosomal dominant disorders involving other coagulation and thrombotic defects.
Gene-modified circulating endothelial progenitor may prove useful in the future
The use of blood outgrowth endothelial cells (BOEC) as a source of cells synthesizing factor VIII has been described. 10 These circulating endothelial progenitor cells are isolated from peripheral blood, expanded in culture, and modified genetically to carry the normal FVIII gene. A significant advantage includes the expansion of BOEC clones that synthesize vWF, the carrier protein necessary for FVIII stability in plasma. Major questions of BOEC use include the half-life of these cells in vivo, and potential for uncontrolled growth following transplantation.
Gene-modified stem cell therapy may become available
Recent reports on the plasticity of stem cells derived from adult tissue forming liver, brain, muscle, skin, fat have generated enormous interest on their use for the genetic correction of hemophilia. A multipotential subset of mesenchymal stem (MAPC) cells derived from marrow stroma can be induced to differentiate into cell types with neuroectoderm, endoderm and mesoderm characteristics. 23 When MAPCs are injected into irradiated animals, they differentiate into hematopoietic lineages as well as epithelium of the liver, gut and lung. Potentially MAPCs could be genetically modified to synthesize coagulation factors before re-transplantation.
Advantages include ex vivo expansion and gene modification with selected clones producing high levels of factor. Autologous stem cells derived from each patient would avoid transplantation rejection and immunosuppression. Current disadvantages include the long lead time (months) required to generate the number of cells for transplantation and the ability to control the differentiated fates of the transplanted multipotential cells.
Summary
A body of data suggests that genetic correction of the hemophilias is feasible. The subjective reporting by patients of decreased bleeding episodes and an apparent self-declared reduction in bleeding episodes at nominal levels of factor strongly hint that reasonable factor levels if reached will achieve a major breakthrough in the treatment of hemophilia. Hemophilia gene transfer represents the combination of vector delivery systems, animal models and clinical studies designed to answer specific questions. Not only will these studies benefit hemophilic patients, but should also instruct others in the field as well. Hopefully, this work will represent a milestone in the use of genetics for treatment of human ailments.
